Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 StudyAditya Bardia, Funda Meric‐Bernstam, Takahiro Kogawa et al.|Journal of Clinical Oncology|2024Cited by 158
Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cellsYumi Fujimoto, Toru Mukohara|Scientific Reports|2020Cited by 86
Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trialToru Mukohara, Patricia LoRusso|Nature Medicine|2024Cited by 50